Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease

J. T. Hutton, W. C. Koller, J. E. Ahlskog, R. Pahwa, H. I. Hurtig, M. B. Stern, B. C. Hiner, A. Lieberman, R. F. Pfeiffer, R. L. Rodnitzky, C. H. Waters, M. D. Muenter, Charles Howard Adler, J. L. Morris

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients with suboptimally controlled Parkinson's disease (PD). The cabergoline patients had significantly better Activities of Daily Living (p = 0.032) and Motor Examination (p = 0.031) scores at the conclusion of the trial compared with the placebo group. The daily levodopa dose for the cabergoline patients decreased 18% compared with a 3% reduction for the placebo group (p < 0.001). The amount of time in the 'on' state increased more in the cabergoline group (p = 0.022). The side-effect profile was similar to that seen with other dopamine agonists, and cabergoline was generally well tolerated. We conclude that cabergoline is an effective adjunct to levodopa for the treatment of PD.

Original languageEnglish (US)
Pages (from-to)1062-1065
Number of pages4
JournalNeurology
Volume46
Issue number4
StatePublished - Apr 1996

Fingerprint

Parkinson Disease
Placebos
Dopamine Agonists
Levodopa
Therapeutics
Activities of Daily Living
cabergoline
Double-Blind Method

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Hutton, J. T., Koller, W. C., Ahlskog, J. E., Pahwa, R., Hurtig, H. I., Stern, M. B., ... Morris, J. L. (1996). Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology, 46(4), 1062-1065.

Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. / Hutton, J. T.; Koller, W. C.; Ahlskog, J. E.; Pahwa, R.; Hurtig, H. I.; Stern, M. B.; Hiner, B. C.; Lieberman, A.; Pfeiffer, R. F.; Rodnitzky, R. L.; Waters, C. H.; Muenter, M. D.; Adler, Charles Howard; Morris, J. L.

In: Neurology, Vol. 46, No. 4, 04.1996, p. 1062-1065.

Research output: Contribution to journalArticle

Hutton, JT, Koller, WC, Ahlskog, JE, Pahwa, R, Hurtig, HI, Stern, MB, Hiner, BC, Lieberman, A, Pfeiffer, RF, Rodnitzky, RL, Waters, CH, Muenter, MD, Adler, CH & Morris, JL 1996, 'Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease', Neurology, vol. 46, no. 4, pp. 1062-1065.
Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI, Stern MB et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology. 1996 Apr;46(4):1062-1065.
Hutton, J. T. ; Koller, W. C. ; Ahlskog, J. E. ; Pahwa, R. ; Hurtig, H. I. ; Stern, M. B. ; Hiner, B. C. ; Lieberman, A. ; Pfeiffer, R. F. ; Rodnitzky, R. L. ; Waters, C. H. ; Muenter, M. D. ; Adler, Charles Howard ; Morris, J. L. / Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. In: Neurology. 1996 ; Vol. 46, No. 4. pp. 1062-1065.
@article{99133c032f2243dab28e2820dbd26c2c,
title = "Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease",
abstract = "Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients with suboptimally controlled Parkinson's disease (PD). The cabergoline patients had significantly better Activities of Daily Living (p = 0.032) and Motor Examination (p = 0.031) scores at the conclusion of the trial compared with the placebo group. The daily levodopa dose for the cabergoline patients decreased 18{\%} compared with a 3{\%} reduction for the placebo group (p < 0.001). The amount of time in the 'on' state increased more in the cabergoline group (p = 0.022). The side-effect profile was similar to that seen with other dopamine agonists, and cabergoline was generally well tolerated. We conclude that cabergoline is an effective adjunct to levodopa for the treatment of PD.",
author = "Hutton, {J. T.} and Koller, {W. C.} and Ahlskog, {J. E.} and R. Pahwa and Hurtig, {H. I.} and Stern, {M. B.} and Hiner, {B. C.} and A. Lieberman and Pfeiffer, {R. F.} and Rodnitzky, {R. L.} and Waters, {C. H.} and Muenter, {M. D.} and Adler, {Charles Howard} and Morris, {J. L.}",
year = "1996",
month = "4",
language = "English (US)",
volume = "46",
pages = "1062--1065",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease

AU - Hutton, J. T.

AU - Koller, W. C.

AU - Ahlskog, J. E.

AU - Pahwa, R.

AU - Hurtig, H. I.

AU - Stern, M. B.

AU - Hiner, B. C.

AU - Lieberman, A.

AU - Pfeiffer, R. F.

AU - Rodnitzky, R. L.

AU - Waters, C. H.

AU - Muenter, M. D.

AU - Adler, Charles Howard

AU - Morris, J. L.

PY - 1996/4

Y1 - 1996/4

N2 - Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients with suboptimally controlled Parkinson's disease (PD). The cabergoline patients had significantly better Activities of Daily Living (p = 0.032) and Motor Examination (p = 0.031) scores at the conclusion of the trial compared with the placebo group. The daily levodopa dose for the cabergoline patients decreased 18% compared with a 3% reduction for the placebo group (p < 0.001). The amount of time in the 'on' state increased more in the cabergoline group (p = 0.022). The side-effect profile was similar to that seen with other dopamine agonists, and cabergoline was generally well tolerated. We conclude that cabergoline is an effective adjunct to levodopa for the treatment of PD.

AB - Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients with suboptimally controlled Parkinson's disease (PD). The cabergoline patients had significantly better Activities of Daily Living (p = 0.032) and Motor Examination (p = 0.031) scores at the conclusion of the trial compared with the placebo group. The daily levodopa dose for the cabergoline patients decreased 18% compared with a 3% reduction for the placebo group (p < 0.001). The amount of time in the 'on' state increased more in the cabergoline group (p = 0.022). The side-effect profile was similar to that seen with other dopamine agonists, and cabergoline was generally well tolerated. We conclude that cabergoline is an effective adjunct to levodopa for the treatment of PD.

UR - http://www.scopus.com/inward/record.url?scp=9244228479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9244228479&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 1062

EP - 1065

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -